This article is more than 5 years old. Information may no longer be current.
AstraZeneca, Adherium partner to combine digital technology with inhaler medications
Click Here to Manage Email Alerts
Adherium Limited and AstraZeneca have agreed to partner to combine digital health technology with the use of inhaler medications, according to a company press release.
Under the agreement, Adherium is expected to supply AstraZeneca with devices and sensors to incorporate into support programs for patients with asthma and COPD.
“These agreements represent a major advance in the treatment and management of respiratory disease, and will make a fundamental difference to the quality of life for people with asthma and COPD,” Garth Sutherland, CEO of Adherium said in the release.
The devices are initially expected to monitor patients’ use of therapy and provide advice to patients on their conditions and medication use, according to the release.
Later developments are intended to include additional sensors designed to monitor a patient’s condition and possibly to determine a patient’s risk factor.
“By providing objective and accurate data on a patient’s medication usage, we can now for the first time develop treatment plans tailored to each patient, and in doing so dramatically improve their quality of life,” Doug Wilson, MD, chairman at Adherium, said in the release.